FDA Files Mifepristone Review Status Report
Federal regulators update their investigation into safety and dispensing practices of common abortion medication.
Updated on Oct. 26, 2026 in Legislative Policy
Live Poll
Should federal rules allowing abortion pills by mail be restricted by state-level abortion bans?
On October 7, 2026, the FDA filed a status report detailing its ongoing review of mifepristone safety and dispensing practices. The agency plans to conclude the investigation between mid-December 2026 and March 2027.
Why it matters
The review follows legal challenges to a 2023 rule that allowed remote prescribing and mail delivery of abortion medication, a practice Louisiana officials argue undermines state bans.
The FDA expects to complete its safety and dispensing review of mifepristone no later than March 2027. This follows a 2023 rule change that removed in-person dispensing requirements for the drug.
The players
FDA
The United States Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs.
Liz Murrill
Liz Murrill is the Attorney General of Louisiana who leads state efforts to challenge federal rules regarding abortion medication access.
Rosalie Markezich
Rosalie Markezich is a Louisiana resident who filed allegations regarding the unauthorized receipt of abortion medication.
The details
The FDA acted after a district court paused litigation to allow for this agency-led review of medical oversight requirements. Louisiana Attorney General Liz Murrill initiated the lawsuit in 2025, citing a case where a resident allegedly received medication without consent, to challenge the legality of non-in-person prescribing.
Timeline
The FDA established the remote prescribing rule in 2023.
Louisiana Attorney General Liz Murrill filed the lawsuit on October 6, 2025.
The Fifth Circuit Court of Appeals ordered reinstated in-person requirements in May 2026.
The FDA submitted its latest status report on October 7, 2026.
Political Context
The litigation marks a direct legal challenge to the 2023 FDA mifepristone dispensing rule. Proponents of the state-led lawsuit argue that the in-person requirement is necessary to protect women from drugs administered without medical oversight.
The ongoing regulatory review and associated court battles determine whether patients can continue to access abortion medication by mail or must travel to clinics. Residents in states with strict bans currently face legal uncertainty regarding their ability to obtain these prescriptions remotely.
The takeaway
The federal government is currently evaluating safety protocols for abortion medication while legal battles proceed through the court system. Affected individuals should monitor local state guidance as court orders regarding medication access remain subject to change.
Further reading
For broader updates on federal oversight, visit the Legislative Policy section.
Source note: This article includes information reported by Reveille.
Live Poll
Should federal rules allowing abortion pills by mail be restricted by state-level abortion bans?
